Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Inflazyme has said that analysis of preliminary results from a study of its asthma drug suggests that there were substantial improvements in asthma control but no difference compared to the placebo group.
Subscribe to our email newsletter
In the phase IIa study, the primary endpoint was an expected improvement in AQLQ compared to placebo and the secondary endpoints incorporated measures of asthma control.
“The profile and magnitude of the placebo response is extremely surprising and merits further examination,” said Dr Kevin Mullane, CEO and president of Inflazyme Pharmaceuticals.
“We are currently conducting a validation review process of the full trial. We expect to report on the outcome of this within the next two to three weeks.”
The company is also expecting to report this quarter on the results of IPL455,903, a non-emetic PDE4 inhibitor which is currently being tested in a phase IIa clinical study in age-associated memory impairment.